RSS Spero Therapeutics Makes Interim Changes To Management After Wells Notice From SEC

Currently reading:
 RSS Spero Therapeutics Makes Interim Changes To Management After Wells Notice From SEC

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
12,004
Likes
1,923
Credits
33,735©
Cash
0$
Spero Therapeutics, Inc. (SPRO) announced on Friday a restructuring within its leadership in response to receiving a Wells Notice from the Securities and Exchange Commission (SEC) regarding certain public disclosures made in 2022. As part of these changes, the company has appointed Esther Rajavelu as Interim Chief Executive Officer, temporarily replacing Sath Shukla, who has agreed to take a voluntary paid administrative leave.

Additionally, the Board has named Frank Thomas as its new Chairman, succeeding Ankit Mahadevia. Despite these alterations, both Shukla and Mahadevia will remain as members of the Board.

The Wells Notice pertains to disclosures the company made from March 31 leading up to its announcement on May 3, 2022, when it decided to halt the commercialization of Tebipenem HBr following feedback from the Food and Drug Administration. The SEC is investigating whether these disclosures may have breached federal securities laws.

Spero has reassured that both Mahadevia and Shukla are actively cooperating with the SEC, asserting that the firm's disclosures were appropriate.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom